IP Library Granted Patent US 7,914,573
Granted Patent B2
US 7,914,573 · App. 11/440,770 · Granted Mar 29, 2011

Polymeric stent having modified molecular structures

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,914,573
App. No.
11/440,770
Granted
Mar 29, 2011
Kind
B2
Abstract

A biocompatible material may be configured into any number of implantable medical devices including intraluminal stents. Polymeric materials may be utilized to fabricate any of these devices, including stents. The stents may be balloon expandable or self-expanding. By preferential mechanical deformation of the polymer, the polymer chains may be oriented to achieve certain desirable performance characteristics.

Claims (6)

1. A substantially tubular intraluminal medical device having a longitudinal axis and a radial axis, the device comprising:

a plurality of hoops formed from a polymeric material, the plurality of hoops comprising a plurality of radial struts and a plurality of radial arcs, the plurality of radial struts having a first amount of alignment via drawing and annealing of the polymer chains in a direction substantially parallel to the longitudinal axis and the plurality of radial arcs having a second amount of alignment via drawing and annealing of the polymer chains in a direction substantially parallel to the radial axis, the first amount of alignment being greater than the second amount of alignment, and wherein the radial struts are thinner than the radial arcs thereby creating high strain zones in the radial struts relative to the radial arcs; and

a plurality of bridges formed from a polymeric material interconnecting the plurality of hoops, wherein the substantially tubular intraluminal medical device has a radial strength in the range from about 13 to 18 psi and an acute recoil at about 13 to 15 percent.

2. The substantially tubular intraluminal device according to claim 1 , further comprising at least one therapeutic agent.

3. The substantially tubular intraluminal device according to claim 2 , wherein the at least one therapeutic agent comprises an antirestenotic agent.

4. The substantially tubular intraluminal device according to claim 3 , wherein the antirestenotic agent comprises a rapamycin.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2025
From: CARDINAL HEALTH SWITZERLAND 515 GMBH; CARDINAL HEALTH 529, LLC; CORDIS CORPORATION; FLEXIBLE STENTING SOLUTIONS, INC
To: CORDIS US CORP
Reel/Frame 072987/0675 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2017
From: CORDIS CORPORATION
To: CARDINAL HEALTH SWITZERLAND 515 GMBH
Reel/Frame 042126/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2007
From: BURGERMEISTER, ROBERT; CONTILIANO, JOSEPH H.; DAVE, VIPUL; LI, YUFU; NARAYANAN, PALLASSANA V.; OVERAKER, DAVID W.; ZHANG, QIANG
To: CORDIS CORPORATION
Reel/Frame 019212/0787 →